BART safety push sees crime drop, ridership rise in 2024
I’ve seen significant improvements over the past couple of years,” said Reece Bell, who normally commutes on BART to work ...
Institute for Fiscal Studies10h
Response to ‘Local authority funding reform: objectives and principles’ consultation by MHCLG
A submission by IFS researchers Kate Ogden and David Phillips to a government consultation on the principles and objectives of council funding reform.
Targeted Oncology13h
Highlights of ASH: Lymphoid Malignancies
ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.
Applied Clinical Trials Online13h
Benchmarking the Investigative Site Qualification Process
Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...
Fierce Pharma13h
Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...
Meta Platforms Ticks All The Right Boxes, Strong Buy
Meta Platforms' financial strength, consistent top and bottom-line growth, and double-digit margins highlight its ...
Medscape15h
Promise for CAR T-Cell Therapies in Solid Tumors?
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
Cancer Therapy Advisor23h
Pembrolizumab Provides “Robust” Clinical Benefit in Clear Cell Gynecologic Cancer
Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.